Dr. Dejan Juric, MD

Dr. Juric practices at Massachusetts General Hospital in Boston, Massachusetts, part of Mass General Brigham.

Dr. Juric's NPI, 1306041975, was assigned on June 15, 2007. Dr. Juric holds Massachusetts license L-231817.

Dr. Juric's primary practice is Massachusetts General Hospital, at 55 Fruit Street, Boston, MA 02114 in Suffolk County. The practice phone is (617) 726-2000.

Dr. Juric's primary practice is Massachusetts General Hospital in Boston, Massachusetts, part of Mass General Brigham. Dr. Juric is also affiliated with Brigham and Women's Hospital. The medical group on file is Massachusetts General Hospital. Dmand AI also links Dr. Juric to 1 more hospital, 3 group practices and clinics, 2 medical groups and 1 community health center, each named with a free account. Dr. Juric's employer is on file too: a hospital.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Juric practices, 7 sites in all. Vendor and product names are available with a free account.

Hematology and oncology is Dr. Juric's primary specialty in the NPI Registry, under taxonomy code 207RH0003X. Dr. Juric is licensed in Massachusetts.

CMS data shows 642 Medicare services from Dr. Juric across 4 procedure codes in 2024, for 105 Medicare patients. Medicare paid $61,081 for them.

CMS counts 105 Medicare patients who saw Dr. Juric in 2024. The largest group is 65 to 74, with 42 patients. 75% of them have cancer, and 62% have high cholesterol. 20% are also on Medicaid. Their average risk score is 2.12, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Juric's median patient age at 71, with 89% women.

In 2024, Dr. Juric wrote 331 Medicare Part D claims for 48 patients. 71% of them were for generic drugs. CMS names the drug for 244 of them, across 13 drugs with 11 or more claims each, at $1,069,351 in total drug cost. In 2023, CMS named 126 claims across 7 drugs.

Dr. Juric accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Juric as offering telehealth.

Dmand AI links 107 papers to Dr. Juric, published from 2012 to 2025. 2024 was the busiest year, with 17. The most frequent topics are Breast Neoplasms, Antineoplastic Combined Chemotherapy Protocols and Protein Kinase Inhibitors. Dr. Juric has published most often in Cancer Discov. Dr. Juric's most frequent co-authors are Aditya Bardia, MD, Steven Jay Isakoff, MD, PhD and Laura M. Spring, MD.

Dmand AI links Dr. Juric to 11 clinical trials, 5 of them phase 1 studies. 4 are still active or recruiting. Conditions studied include Breast Neoplasms, Small Cell Lung Carcinoma and Breast Diseases. Novartis Pharmaceuticals sponsors the most, 4. Open Payments lists research payments to Dr. Juric that name 1 trial.

CMS Open Payments shows 169 general payments to Dr. Juric from 13 drug and device companies from 2016 to 2025. Consulting fees make up the largest share, 68% of the total. Novartis Pharmaceuticals Corporation paid the most, $143,435. It also lists 60 research payments totaling $51,004 from 2016 to 2025, naming 1 clinical trial.